Bortezomib in relapsed multiple myeloma: Response rates and duration of response are independent of a chromosome 13q-deletion

Leukemia

Volumn 21, Issue 1, 2007, Pages 164-168

  Sagaster, V ^a   Ludwig, H ^b   Kaufmann, H ^a   Odelga, V ^a   Zojer, N ^b   Ackermann, J ^a   Kuenburg E ^b   Wieser, R ^a   Zielinski, C ^a   Drach, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; PARAPROTEIN; THALIDOMIDE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; INTERPHASE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT FAILURE;

EID: 33845524012     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404459     Document Type: Article

References (29)

1. Attal M, Harousseau J-L, Stoppa A-M, Sotto J-L, Fuzibet J-G, Rossi J-F et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996; 335: 91-97.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 95: 2615-2622.
4. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
5. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 4996-5000.
6. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai Y-T, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-2380.
7. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
8. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
9. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106: 2977-2981.
10. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA et al. Plasma cell labeling index and beta 2-microglobulin predicr survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-3387.
11. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta 2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
12. Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
13. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
14. Zojer N, Königsberg R, Ackermann J, Fritz E, Dallinger S, Kroömer E et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridisation. Blood 2000; 95: 1925-1930.
15. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (D13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res 2002; 62: 715-720.
16. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004; 64: 1546-1558.
17. Kroeger N, Schilling G, Einsele H, Liebisch P, Simoni A, Nagler A et al. Deletion of chromosome band 13q14 as detected by FISH is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103: 4056-4061.
18. Durie BGM, Salmon SE. A clinial staging system for multiple myeloma. Cancer 1975; 36: 842-854.
19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Garton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation: Myeloma subcommittee of the EBMT. Br J Haematol 1998; 102: 1115-1123.
20. Ackermann J, Meidlinger P, Zojer N, Gisslinger H, Ludwig H, Huber H et al. Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. Br J Haematol 1998; 103: 1161-1163.
21. Kaufmann H, Ackermann J, Baldia C, Nosslinger T, Wieser R, Seidl S et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18: 1879-1882.
22. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579-1583.
23. Gertz MA, Lacy MQ, Disperenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical impact of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and 17p53 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837-2840.
24. Chang H, Qi XY, Samiee S, Yi OL, Chen C, Trudel S et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 2005; 36: 793-796.
25. Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J et al. Clinical outcome in t(4;14) multiple myeloma: A chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23: 7069-7073.
26. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory mutiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
27. Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J et al. Prognostic impact of cytogenetics and interphase FISH-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II. Br J Haematol 2003; 120: 44-52.
28. Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S et al. Relationship of patient survival and chromosome anomalities detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005; 106: 3553-3558.
29. Shaughnessy J, Zhan F, Barlogie B, Stewart AK. Gene expression profiling and multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 537-552.